Mounjaro is a prescription medication manufactured by Eli Lilly and Company, an American pharmaceutical company founded in 1876. Its active ingredient is tirzepatide. Mounjaro is administered via a once-weekly subcutaneous injection. It is available both as a single-dose autoinjector pen or a multi-dose prefilled KwikPen. The KwikPen contains 4 fixed doses. Mounjaro was initially FDA-approved in May 2022 to improve blood sugar control in adults and children 10 years and older with type 2 diabetes, when used in conjunction with diet and exercise. Tirzepatide has also been shown to aid with weight loss and weight management in clinical trials.
Mounjaro functions as a dual agonist, activating both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors in the body. By activating these receptors, tirzepatide stimulates insulin release when glucose levels are high, reduces glucagon production by the liver, slows down stomach emptying to control sugar spikes after meals, and increases feelings of fullness, thereby reducing appetite and food intake. Mounjaro is available in various dosages, ranging from 2.5 mg to 15 mg. The typical cost of Mounjaro without insurance ranges from $1,000 to $1,200 per month. However, with commercial insurance, eligible patients may pay as little as $25 for a one to three-month supply. Mounjaro is generally available, although temporary shortages may occur due to high demand.
